FOLFIRINOX plus cetuximab (CET) or bevacizumab (BEV) in patients (pts) with initially unresectable colorectal liver metastases (CRLM) with BRAF mutated (mut) tumors: A subgroup analysis of the UNICANCER PRODIGE 14-ACCORD 21 (METHEP2) trial.

Congress : ASCO

Authors : E. Lopez-Crapez,  A. Adenis, S. Thezenas, E. Assenat, E. François, R. Guimbaud, M. Chauvenet, F. Khemissa6, F. Audemar, E. Suc,  M Rivoire, F. Ghiringhelli, A. Mercier-Blas, L. Mineur, Y. Becouarn, P. Houyau, T. Stanbury, C. Jouffroy-Zeller, O. Bouché, M. Ychou

Experts group or program : Groupe gastro-intestinal (UCGI)

The treatment of metastatic colorectal cancer (mCRC) pts with BRAF-mut tumors is a major challenge for physicians. They account for < 10% of mCRC, correlate with poor prognosis, and respond poorly to standard first-line regimens including chemotherapy doublets (2-CT) plus a targeted agent. Guidelines suggest treating BRAF-mut mCRC with a triplet CT regimen (3-CT; fluorouracil, irinotecan, and oxaliplatin combination) plus BEV, based on a subgroup analysis of the TRIBE study. In this analysis of 16 mCRC pts with BRAF-mut tumors, median PFS (mPFS) and OS (mOS) were 7.5 and 19 months (mo), respectively. Since the impact of 3-CT plus CET on outcomes in pts with BRAF-mut tumors is largely unexplored, we aimed to assess this subpopulation in the METHEP2 trial.

En savoir plus